Epstein-Barr virus (EBV) is almost certainly a required trigger for multiple sclerosis. A landmark 2022 study tracking over 10 million US military personnel found that EBV infection increased the risk of developing MS by 32-fold, while infection with other viruses, including the closely related cytomegalovirus, did not increase risk at all. Virtually 99.5 to 100% of people with MS test positive for EBV antibodies, compared to about 94% of healthy adults. The evidence is now strong enough that most researchers consider EBV a necessary cause of MS, though not the only factor involved.
The Study That Changed the Debate
For decades, scientists suspected a link between EBV and MS but couldn’t prove the virus came first. That changed with a study published in Science in 2022 that analyzed blood samples collected from military service members over a 20-year period. Researchers could track who was EBV-negative at enrollment, who later became infected, and who eventually developed MS.
The results were striking. People who contracted EBV during the study period had a 32-fold increased risk of later developing MS. Those who were already EBV-positive at enrollment had a 26-fold increased risk. No other viral infection showed this pattern. The comparison with cytomegalovirus was especially telling: it spreads through similar routes as EBV, yet carried no MS risk at all, ruling out the possibility that the association was simply about general immune activation or shared lifestyle factors.
How the Virus Tricks the Immune System
The leading explanation is a process called molecular mimicry. One of EBV’s key proteins looks structurally similar to a protein called GlialCAM, which sits on the surface of cells that insulate nerve fibers in the brain and spinal cord. When the immune system builds antibodies to fight EBV, some of those antibodies also recognize and attack GlialCAM. Research published in Nature Immunology showed that this cross-reactivity worsens over time: as immune cells mature inside the central nervous system, their ability to bind GlialCAM increases through a process of antibody refinement. In other words, an immune response that starts out targeting the virus gradually becomes an autoimmune attack on the brain’s own tissue.
EBV also reshapes the immune system in a more direct way. The virus infects a type of white blood cell called memory B cells and hides inside them for life. Once infected, these B cells produce inflammatory signals and can drive other immune cells toward aggressive, tissue-damaging behavior. Some research has found EBV-infected B cells with neuroinvasive properties, meaning they can cross into the brain. Studies in mice carrying the same genetic risk factor found in many MS patients showed that EBV infection triggered these B cells to migrate into the central nervous system, potentially seeding the conditions for MS.
Why Most People With EBV Never Get MS
Over 90% of adults worldwide carry EBV, yet fewer than 1 in 300 develop MS. EBV is considered a necessary but not sufficient cause of the disease. Several other factors appear to determine who actually progresses.
Genetics plays a major role. The single strongest genetic risk factor for MS is a specific immune gene variant called HLA-DRB1*15:01. Recent research revealed that this gene variant actually functions as a co-receptor for EBV, helping the virus infect B cells more efficiently. People who carry this variant and contract EBV may harbor higher viral loads or have a harder time keeping the virus in check, both of which could tip the balance toward autoimmunity.
MS patients consistently have higher levels of EBV-specific antibodies than healthy people who also carry the virus. This suggests their immune systems are struggling to keep latent EBV under control, mounting repeated, escalating responses that increase the chance of collateral damage to nerve tissue.
Vitamin D and Other Environmental Factors
Low vitamin D levels are independently linked to higher MS risk, and the interaction with EBV may explain why. Vitamin D helps regulate immune function, and when levels are low, the immune system is less effective at suppressing EBV-infected cells. This allows those cells to proliferate more freely, amplifying the abnormal immune responses that drive MS. The connection helps explain a long-standing observation: MS is far more common at higher latitudes, where people get less sun exposure and tend to have lower vitamin D levels, especially during childhood and adolescence.
Having symptomatic mono (infectious mononucleosis) rather than a silent EBV infection also matters. MS is more than twice as common in people who experienced mono, likely because a more intense initial infection produces a stronger and more persistent immune response to the virus.
Why B-Cell Therapies Work So Well
One of the most effective treatments for relapsing MS works by depleting B cells, the very cells where EBV hides. These therapies wipe out memory B cells that harbor the virus and produce inflammatory signals. When B cells eventually repopulate after treatment, they tend to come back with an anti-inflammatory profile rather than a pro-inflammatory one.
This is essentially an indirect form of anti-EBV therapy. By removing the cells the virus lives in, the treatment eliminates a major source of the immune dysfunction that drives relapses. The dramatic effectiveness of B-cell depletion in MS is itself considered supporting evidence for the EBV theory: if EBV-infected B cells are central to the disease, then removing those cells should help, and it does.
EBV Vaccines and the Future of Prevention
If EBV is a required trigger, then preventing or controlling EBV infection could theoretically prevent MS. This idea is now being tested directly. Moderna has a Phase 2 clinical trial underway for mRNA-1195, an experimental vaccine being studied in people aged 18 to 55 who already have MS and are EBV-positive. The trial is designed to see whether boosting the immune response against EBV can reduce MS relapses.
Separate efforts are focused on preventive EBV vaccines that could be given before initial infection, similar to the HPV vaccine strategy. If a vaccine could prevent EBV infection in childhood or adolescence, it might eliminate the most critical environmental trigger for MS entirely. That possibility, once speculative, now has a strong scientific foundation behind it.